Seven children with Allan-Herndon-Dudley syndrome (AHDS), a rare genetic disorder, are set to receive a year's supply of the medicine tiratricol free of cost on November 30, following an initiative led by Hyderabad-based paediatrician Dr Sivaranjani Santosh and Access to Medicines India. The cost of the treatment was brought down through pharmaceutical compounding in the Netherlands. While the commercial version of the drug costs approximately ₹4.68 crore to ₹9 crore per child annually, the compounded formulation is estimated to cost just ₹2.5 lakh per child for a year.

The medicine was prepared by Transvaal Pharmacy in The Hague with support from the Netherlands-based Pharmaceutical Accountability Foundation (PAF). The first batch will be handed over to the parents of the seven children along with the necessary documentation and individual import permissions. As the compounded medicine has a shelf life of six months, it will be imported in two batches.

The initiative began after Arav, a child under Dr Sivaranjani's care, was diagnosed with AHDS, also known as MCT8 deficiency, caused by mutations affecting the MCT8 gene. Arav's mother, Pavitra Sirolkar, had to arrange approximately ₹12 lakh to ₹13 lakh for just one month's supply of the medicine from Germany. After attempts to obtain the drug through pharmaceutical company Egetis Therapeutics and its compassionate-use programme did not succeed, Dr Sivaranjani posted an appeal on social media on September 7, which brought the issue to PAF's notice.

According to PAF, the total cost of providing one year's treatment to all seven children is €14,200, approximately ₹15.08 lakh. Of this, Dr Sivaranjani raised approximately ₹6.09 lakh in India, while PAF undertook to raise the remaining €8,600, approximately ₹9.13 lakh, in the Netherlands. Dr Sivaranjani said importing the medicine cannot be a permanent solution and that she plans to approach the Union government to explore getting it compounded in India.